Among the variety of resistance mechanisms that may underlie a non-optimal response to TKI therapy in CML patients, secondary point mutations in within the region of BCR::ABL1 encoding the TKD are the only ones that are clinically actionable. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.